In the Specification:

Please amend the paragraph beginning at page 1, line 31 of the specification as follows:

--Co-pending PCT application No. ~~PCT/GB02/05743~~ PCT/GB02/05738 discloses compounds of formula A



A

wherein n is 1 or 2 and optical isomers and racemates thereof, pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof are highly potent PPARα modulators. PPAR is short peroxisome proliferator-activated receptors (for for a review of the PPARs see T. M.Willson et al , J Med Chem 2000, Vol 43, 527). These compounds are effective in treating conditions associated with insulin resistance. Specific pharmaceutically acceptable salts of compounds of the formula A are not disclosed in ~~PCT/GB02/05743~~ PCT/GB02/05738. Further, no information is provided in relation to how crystalline forms of compounds of the formula A, and particularly salts thereof, may be prepared. The compound in which n is 2 is prepared as the free acid in this application. However, this compound is a syrup and is thus not suitable for use in pharmaceutical formulations. Therefore there exists a need for a derivative of this compound which has physical and chemical properties suitable for use in pharmaceutical formulations. Attempts were made to produce salts with many different counter-ions. However, most were unsatisfactory for one of the following reasons. A salt could not be formed in the solid state or if formed the salt was amorphous with a low glass transition temperature.--

Please amend the paragraph beginning at page 4, line 23 of the specification as follows:

--Compounds of the invention, and particularly crystalline compounds of the invention, may have improved stability when compared to compounds disclosed in ~~PCT/GB02/05743~~ PCT/GB02/05738.--